Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

The Sarcoma Channel is supported with funding from Iovance Biotherapeutics (Silver).

VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.

Share this video  

VJVirtual | Treatment of KIT exon 9-mutated GISTs

Robin Jones, MD, The Royal Marsden Hospital, London, UK, talks on a retrospective study on the biology and treatment of KIT exon 9 mutations in gastrointestinal stromal tumors (GISTs), including the investigation of 131 patients who harbor a KIT exon 9 mutation receiving a starting dose of either 800mg or 400mg imatinib per day. No significant difference was found between the survival outcomes of patients receiving either starting dose.

Choose your cookie settings

VJOncology uses necessary cookies to make the site work. With your permission we'd also like to use analytics, preference and marketing cookies to understand how the site is used and improve it.

Choose an option to continue. You can change it at any time on our Cookie Policy page, linked at the bottom of every page.